WO2023067561 - IONIZABLE CATIONIC LIPID FOR MESSENGER RNA DELIVERY
National phase entry:
Publication Number
WO/2023/067561
Publication Date
27.04.2023
International Application No.
PCT/IB2022/060126
International Filing Date
21.10.2022
Title **
[English]
IONIZABLE CATIONIC LIPID FOR MESSENGER RNA DELIVERY
[French]
LIPIDE CATIONIQUE IONISABLE POUR L'ADMINISTRATION D'ARN MESSAGER
Applicants **
SEQIRUS INC.
Inventors
DANE, Eric L.
Priority Data
63/270,603
22.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
USPTO
* |
| * | |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2592 | |
| EPO | Filing, Examination, Granting | 14995 | |
| Japan | Filing, Examination, Granting | 2277 | |
| South Korea | Filing, Examination, Granting | 2398 | |
| USA | Filing, Examination, Granting | 5510 |
Total:
27,772
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The use of an ionizable cationic lipid in forming lipid nanoparticles is described. The lipid nanoparticles may encapsulate a therapeutic, such as a nucleic acid, including conventional messenger RNA and self-amplifying messenger RNA, and may be used in the delivery of the therapeutic and in methods of treating certain conditions, or for inducing an immune response.[French]
L'invention concerne l'utilisation d'un lipide cationique ionisable dans la formation de nanoparticules lipidiques. Les nanoparticules lipidiques peuvent encapsuler un agent thérapeutique, tel qu'un acide nucléique, comprenant un ARN messager classique et un ARN messager auto-amplifiant, et peuvent être utilisées dans l'administration de l'agent thérapeutique et dans des méthodes de traitement de certains états pathologiques, ou pour induire une réponse immunitaire.